KURA
Kura Oncology, Inc. · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers): breedte van houders 0.0% · aandelenstroom +22.0% · netto nieuwe posities 0.0% — formule
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2024
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 85 | +3 | 46.85M | $513.57M | +7 | −4 |
| Q1 2026 | 85 | 0 | 43.54M | $354.05M | +5 | −5 |
| Q4 2025 | 85 | 0 | 47.00M | $488.20M | +1 | −1 |
| Q3 2025 | 15 | -1 | 31.70M | $280.57M | — | −1 |
| Q2 2025 | 13 | 0 | 25.43M | $146.75M | — | — |
| Q1 2025 | 10 | 0 | 9.58M | $63.25M | — | — |
| Q4 2024 | 10 | -1 | 11.52M | $100.37M | +1 | −2 |
| Q3 2024 | 10 | 0 | 4.92M | $96.24M | +1 | −1 |
| Q2 2024 | 10 | — | 4.04M | $83.12M | — | — |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passief) | 1.78M | +2.4% | $34.80M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passief) | 1.78M | +2.4% | $34.80M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 1.19M | +17.4% | $23.23M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Millennium Management ✦ | 845.19K | +149.0% | $16.52M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | D. E. Shaw & Co. ✦ | 423.21K | +12.6% | $8.27M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | D. E. Shaw & Co. ✦ | 423.21K | +12.6% | $8.27M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 208.24K | -23.5% | $4.07M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | Point72 Asset Management ✦ | 189.10K | Nieuw | $3.70M | 0.0% | New | 1 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 122.52K | +50.0% | $2.39M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 122.52K | +50.0% | $2.39M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 122.52K | +50.0% | $2.39M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Renaissance Technologies ✦ | 106.11K | -12.4% | $2.07M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | Wellington Management ✦ | 37.30K | -16.8% | $728,880 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 14 | Wellington Management ✦ | 37.30K | -16.8% | $728,880 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | Wellington Management ✦ | 37.30K | -16.8% | $728,880 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 16 | Wellington Management ✦ | 37.30K | -16.8% | $728,880 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | T. Rowe Price ✦ | 23.73K | +2.9% | $464,000 | 0.0% | ▲ Add | 2 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Point72 Asset Management | $3.70M | 0.0% |
Verlaten
| Marshall Wace | $540,838 | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 217 houders, 84.35M aandelen, $677.88M gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Officer, Director · President and CEO · 100.00K aand @ 12.39 · $1.24M
Officer, Director · President and CEO · 100.00K aand @ 11.12 · $1.11M
Open-market verkopen (S)
Officer · 4.34K aand · $51,663
Officer · 31.49K aand · $397,681
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie